These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38520081)

  • 1. Metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort.
    Garrido-Torres N; Ruiz-Veguilla M; Olivé Mas J; Rodríguez Gangoso A; Canal-Rivero M; Juncal-Ruiz M; Gómez-Revuelta M; Ayesa-Arriola R; Crespo-Facorro B; Vázquez-Bourgon J
    Span J Psychiatry Ment Health; 2023; 16(3):175-183. PubMed ID: 38520081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort.
    Garrido-Torres N; Ruiz-Veguilla M; Alameda L; Canal-Rivero M; Ruiz MJ; Gómez-Revuelta M; Ayesa-Arriola R; Rubio-García A; Crespo-Facorro B; Vázquez-Bourgon J
    Schizophr Res; 2022 Aug; 246():277-285. PubMed ID: 35878542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis.
    Garrido-Torres N; Rocha-Gonzalez I; Alameda L; Rodriguez-Gangoso A; Vilches A; Canal-Rivero M; Crespo-Facorro B; Ruiz-Veguilla M
    Psychol Med; 2021 Oct; 51(14):2307-2320. PubMed ID: 34493353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial.
    Jensen KG; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JRM; Fink-Jensen A; Pagsberg AK
    J Clin Psychiatry; 2017; 78(8):e1035-e1046. PubMed ID: 28102978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal.
    Coentre R; Levy P; Góis C; Figueira ML
    J Int Med Res; 2022 Jun; 50(6):3000605221106703. PubMed ID: 35726606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.
    Balõtšev R; Haring L; Koido K; Leping V; Kriisa K; Zilmer M; Vasar V; Piir A; Lang A; Vasar E
    Early Interv Psychiatry; 2019 Feb; 13(1):101-109. PubMed ID: 28719155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
    Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study.
    Galiano Rus S; Ortiz García de la Foz V; Arias-Loste MT; Iruzubieta P; Gómez-Revuelta M; Juncal-Ruiz M; Crespo J; Crespo-Facorro B; Vázquez-Bourgon J
    Schizophr Res; 2022 Aug; 246():30-38. PubMed ID: 35696859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort.
    Vázquez-Bourgon J; Gómez-Revuelta M; Mayoral-van Son J; Labad J; Ortiz-García de la Foz V; Setién-Suero E; Ayesa-Arriola R; Tordesillas-Gutiérrez D; Juncal-Ruiz M; Crespo-Facorro B
    Eur Psychiatry; 2022 Aug; 65(1):e48. PubMed ID: 35971658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of serum glucose, triglycerides, and high-density lipoprotein cholesterol on cardiovascular risk factor burden in nondiabetic, obese African American women: implications for the prevalence of metabolic syndrome.
    Gaillard T; Schuster D; Osei K
    Metabolism; 2010 Aug; 59(8):1115-23. PubMed ID: 20051282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up.
    Nyboe L; Vestergaard CH; Moeller MK; Lund H; Videbech P
    Schizophr Res; 2015 Oct; 168(1-2):381-7. PubMed ID: 26278336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study).
    O'Donoghue B; Allott K; Harrigan S; Scalzo F; Ward J; Mallawaarachchi S; Whitson S; Baldwin L; Graham J; Mullen E; MacNeil C; Alexander D; Wood SJ; Berk M; Alvarez-Jimenez M; Thompson A; Fornito A; Yuen HP; Nelson B; Francey SM; McGorry P
    Early Interv Psychiatry; 2023 Jun; 17(6):597-607. PubMed ID: 36196478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for metabolic syndrome in individuals with recent-onset psychosis at disease onset and after 1-year follow-up.
    Alonso Y; Miralles C; Algora MJ; Valiente-Pallejà A; Sánchez-Gistau V; Muntané G; Labad J; Vilella E; Martorell L
    Sci Rep; 2022 Jul; 12(1):11386. PubMed ID: 35794221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis.
    Nettis MA; Pergola G; Kolliakou A; O'Connor J; Bonaccorso S; David A; Gaughran F; Di Forti M; Murray RM; Marques TR; Blasi G; Bertolino A; Pariante CM; Dazzan P; Mondelli V
    Psychoneuroendocrinology; 2019 Jan; 99():145-153. PubMed ID: 30243054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients.
    Gjerde PB; Simonsen CE; Lagerberg TV; Steen NE; Ueland T; Andreassen OA; Steen VM; Melle I
    Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):49-58. PubMed ID: 31028479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.
    Graham KA; Cho H; Brownley KA; Harp JB
    Schizophr Res; 2008 Apr; 101(1-3):287-94. PubMed ID: 18255275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?
    Zhang T; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Xie B; Li C; Wang J
    Aust N Z J Psychiatry; 2021 Mar; 55(3):314-323. PubMed ID: 33143440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics.
    Panagiotopoulos C; Ronsley R; Kuzeljevic B; Davidson J
    Can J Psychiatry; 2012 Jan; 57(1):34-44. PubMed ID: 22296966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.
    Vázquez-Bourgon J; Mayoral-van Son J; Gómez-Revuelta M; Juncal-Ruiz M; Ortiz-García de la Foz V; Tordesillas-Gutiérrez D; Ayesa-Arriola R; Bioque M; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):1-7. PubMed ID: 32840607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.